Virginia Commonwealth University opened the $87 million College of Health Professions in March of 2019 in Richmond. Designed by EYP Architecture and Engineering, the eight-story, 154,000-gsf facility unites nine departments in a sustainably designed structure that is expected to attain LEED Silver certification.
Bluebird Bio opened a 125,000-sf gene and cell therapy manufacturing facility in March of 2019 in Durham, N.C. Representing an $80 million investment, the project is bluebird's first wholly owned facility and will support the production of lentiviral vector for clinical and commercial applications. The building, which is now substantially complete and undergoing equipment commissioning, provides multiple manufacturing suites, quality-control testing labs, and warehouse space.
Inova Health System will open the 342,000-sf Schar Cancer Institute in May of 2019 in Fairfax, Va. Designed by Wilmot Sanz to provide comprehensive cancer care services in a single location, the patient-centric facility offers 124 exam rooms, 54 infusion chairs, diagnostic suites, advanced radiation therapy modalities, and a genetic counseling clinic.
Stanford University opened the $107 million Anne T. and Robert M. Bass Biology Research Building in March of 2019 in Palo Alto, Calif. Designed by Flad Architects and Ennead Architects to promote collaboration and interaction, the 133,000-sf facility provides wet biochemistry labs, dry computational labs, hybrid wet/dry research areas, and classrooms and offices for the Department of Biology.
Merck opened the first M Lab™ Collaboration Center in Europe in March of 2019. Located in Molsheim, France, the facility provides biopharmaceutical customers with a shared, exploratory environment where they can work with Merck scientists and engineers to accelerate the manufacture of new therapies. The 43,000-sf facility offers advanced simulation technologies in a non-GMP environment for end-to-end process development from pre-clinical through full-scale production.
Eisai is building the $100 million Center for Genetics Guided Dementia Discovery (G2D2) in Cambridge, Mass. Sited in the newly constructed Alewife Research Center, the 50,000-sf neuroscience facility will support exploratory drug research on next-generation dementia therapeutics. Featuring numerous interaction zones and huddle areas, the center will provide open offices, a collaboration hub, flexible meeting rooms, and multidisciplinary open labs for the study of biology, chemistry, and automation.
Vermeulens has released its market outlook report for the fourth quarter of 2018. Key points include:
Arizona State University and Wexford Science+Technology broke ground in March of 2019 on a $77 million research building on the Phoenix Biomedical Campus. The public-private project will be owned by Wexford and is being created in partnership with Ventas and the city of Phoenix. Half of the seven-story, 225,000-sf facility will house research labs for ASU's Biodesign Institute, the College of Health Solutions, and the College of Nursing and Health Innovation.
Cellectis entered into a lease agreement in March of 2019 to build the Innovative Manufacturing Plant for Allogeneic Cellular Therapies (IMPACT) in Raleigh, N.C. Designed by Laporte Euro, the facility will produce immunotherapies based on gene-edited allogeneic CAR T-cells (UCART). Colliers International assisted in the real estate transaction. In addition, Cellectis is building a 14,000-sf manufacturing facility in Paris.
Quest Diagnostics broke ground in March of 2019 on a 250,000-sf laboratory in Clifton, N.J. The medical testing facility will be Quest's largest development and will accommodate over 1,100 employees. Supporting increased capacity, the center will provide comprehensive diagnostic services with reduced processing times. Occupancy is expected in 2021. The lab is located on 12 acres in the ON3 campus which offers integrated research, office, and residential facilities in a vibrant environment offering myriad lifestyle amenities.
Lehigh University is planning to build a $100 million facility for the College of Health in Bethlehem, Pa. Designed by Wilson HGA, the five-story, 190,000-gsf facility will promote interdisciplinary education and research by collocating programs in health, science, and technology. Featuring a transparent design with minimal hard walls, the project will offer open labs and learning studios to enhance collaboration and interaction.
Amicus Therapeutics is creating the Global Research and Gene Therapy Center of Excellence in Philadelphia. The 75,000-sf facility will provide collaborative laboratories and offices for the discovery and development of treatments for rare metabolic diseases. Accommodating up to 200 employees, the center will serve as the headquarters for the global Amicus science organization and the gene therapy division’s leadership team. Occupancy is expected in the second half of 2019.
Akouos, a genetic medicine company, has leased 37,500 sf in Boston for its research headquarters. The facility is located in a two-story, 150,000-sf building at 645 Summer Street and will support the discovery and commercialization of therapies for hearing disorders. The project was developed by Pappas Enterprises and renovated by Tocci Building Corporation. The sustainably designed structure has attained LEED Silver certification.
Rosalind Franklin University is building the $50 million Innovation and Research Park in North Chicago, Ill. The four-story, 100,000-sf facility will provide leading-edge research labs, business incubator space, meeting rooms, and common areas. The project will promote collaboration among faculty, industry scientists, and biotech entrepreneurs in order to accelerate the discovery and commercialization of new medical treatments and therapeutics.
Autolus Therapeutics has signed a long-term, full-building lease with Alexandria Real Estate Equities for the construction and development of a build-to-suit facility in Rockville, Md. Located in the Shady Grove Life Sciences Center, the 85,000-sf project will accommodate the company's U.S. headquarters and a commercial-scale manufacturing center for cell therapies. Occupancy is expected in 2021.
